A 10-year perspective on donepezil

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 331-338

  Cheewakriengkrai, Laksanun ^a   Gauthier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Donepezil; Mild cognitive impairment

Indexed keywords

DONEPEZIL; TACRINE;

ABNORMAL DREAMING; ALZHEIMER DISEASE; ANOREXIA; ARTHRITIS; BACKACHE; BLEEDING; COGNITION; CONFUSION; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DEHYDRATION; DEPRESSION; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG URINE LEVEL; ECCHYMOSIS; ECZEMA; FAINTNESS; FATIGUE; HALLUCINATION; HEALTH CARE COST; HOSTILITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INSOMNIA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; NAUSEA; NERVOUSNESS; PAIN; PARASOMNIA; PERSONALITY DISORDER; POLLAKISURIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT WITHDRAWAL; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; HALF-LIFE; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84873403514     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.760543     Document Type: Review

References (37)

1. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2(6150):1457-9 (Pubitemid 9061468)
2. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10(2):122-6 (Pubitemid 11053099)
3. Drachman DA, Glosser G, Fleming P, et al. Memory decline in the aged Treatment with lecithin and physostigmine. Neurology 1982;32(9):944
4. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-Term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315(20):1241-5 (Pubitemid 17049681)
5. Rogers S, Friedhoff L. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-Controlled trial. Dement Geriatr Cogn Disord 1996;7(6):293-303 (Pubitemid 26341258)
6. Rogers S, Farlow M, Doody R, et al. A 24-week, double-blind, placebo-Controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50(1):136-45
7. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmaco. Ther Toxicol 1993;31(5):223
8. Tiseo P, Foley K, Friedhoff L. Concurrent administration of donepezil HCl and theophylline: Assessment of pharmacokinetic changes following multiple-Dose administration in healthy volunteers. Br J Clinl Pharmacol 1998;46(S1):35
9. Tiseo P, Foley K, Friedhoff L. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(S1):45
10. Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(S1):25
11. Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and digoxin: Assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998;46(S1):40
12. Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(S1):30
13. Rogers S, Walters E, Friedhoff L. The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 ((R, S)-1-benzyl-4-((5, 6-Dimethoxy-1-indanon)-2- yl)-methylpiperidine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): Implications for use in Alzheimer's disease. Neurobiol Aging 1992;13(SUPPL1):S125-S6
14. Tiseo P, Foley K, Friedhoff L. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. British Journal of Clinical Pharmacology 1998;46(S1):56
15. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-88 (Pubitemid 40958434)
16. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment A randomized placebo-Controlled trial. Neurology 2004;63(4):651-7 (Pubitemid 39100820)
17. Burns A, Rossor M, Hecker J, et al. The Effects of Donepezil in Alzheimer's Disease-Results from a Multinational Trial1. Dement Geriatr Cogn Disord 1999;10(3):237-44 (Pubitemid 29224502)
18. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(6):299-313
19. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-Controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57(3):489-95 (Pubitemid 32757598)
20. Mohs RC, Doody R, Morris J, et al. A 1-year, placebo-Controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57(3):481-8 (Pubitemid 32757597)
21. Rogers S, Doody R, Pratt R, et al. Long-Term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-Label study. Eur Neuropsychopharmacol 2000;10(3):195-203 (Pubitemid 30227620)
22. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14(4):389-404 (Pubitemid 36331605)
23. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57(4):613-20 (Pubitemid 32782987)
24. Winblad B, Kilander L, Eriksson S. Donepezil in patients with severe Alzheimer's disease. Lancet 2006;367:1057-65
25. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-Dose (23 mg/d) versus standard-Dose (10 mg/d) donepezil in moderate to severe alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010;32(7):1234-51
26. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week, multicenter, international, randomized, placebo-Controlled clinical trial. Stroke 2003;34(10):2323-30 (Pubitemid 37221934)
27. Malouf R, Birks J. Evidence of efficacy of donepezil for people with mild or moderate vascular cognitive impairment. 2009
28. Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies Response of delirium-Like features to donepezil. Neurology 1998;51(5):1512 (Pubitemid 28520601)
29. Aarsland D, Brønnick K, Karlsen K. Donepezil for dementia with Lewy bodies: A case study. Int J Geriatr Psychiatry 1999;14(1):69-72 (Pubitemid 29046039)
30. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: A randomized, placebo-Controlled trial. Ann Neurol 2012;72(1):41-52
31. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. Mov Disord 2012;27(10):1230-8
32. Aarsland D, Laake K, Larsen J, et al. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72(6):708-12 (Pubitemid 34557010)
33. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76(7):934-9 (Pubitemid 40909549)
34. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51(7):937-44 (Pubitemid 36871141)
35. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47(5):570
36. Gauthier S, Patterson C, Chertkow H, et al. 4th Canadian consensus conference on the diagnosis and treatment of dementia. Can J Neurol Sci 2012;39(SUPPL5):6
37. Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18(4):282-4 (Pubitemid 36503036)